CN Stock MarketDetailed Quotes

600513 Jiangsu Lianhuan Pharmaceutical

Watchlist
  • 8.92
  • -0.36-3.88%
Market Closed Oct 11 15:00 CST
2.55BMarket Cap18.66P/E (TTM)

About Jiangsu Lianhuan Pharmaceutical Company

The company was founded in December 1999 by Yangzhou Pharmaceutical Factory, which was founded in 1958, and successfully landed on the Shanghai main board in March 2003. It currently has 3 high-tech enterprises and 2 “specialized, special and new” enterprises at the provincial level, and has won titles such as “China's Top 100 Chemical Industry Enterprises”, “National Intellectual Property Demonstration Enterprise”, “Jiangsu Excellent Enterprise”, and “National Enterprise for Integrating the Two Technologies”. In 2023, the company was successfully selected to establish a world-class professional leading demonstration enterprise, becoming the first batch of two local state-owned enterprises in the country, two in Jiangsu, and the only local state-owned enterprises in the city to receive this honor. The company's industry is pharmaceutical manufacturing. It is a national high-tech enterprise integrating R&D, production and sales. The company's main business covers the fields of pharmaceutical manufacturing and pharmaceutical distribution. The company's main products include several series of urological drugs, antihistamines, cardiovascular drugs, steroidal hormones, antibiotics, etc., covering various pharmaceutical forms of chemical raw materials, injections, and solid preparations, including the national first-class drug Eprit tablets (Sichuan), the second-class new drug ebastine tablets (Sudi), and felodipine tablets (bicyclidine), danazol capsules and suppositories, metformin glitzide tablets (dosa), lumkinase capsules, sertraline hydrochloride capsules (optimal cyclic determination)), dapoxetine hydrochloride tablets, tadalafil tablets, temozolomide capsules, abiraterone acetate tablets, moxifloxacin hydrochloride tablets, ebastine Products such as oral liquids. The company was successfully selected to create a world-class “specialized, special and new” model enterprise; was recognized by the Jiangsu Provincial Department of Industry and Information Technology as the second batch of provincial star cloud enterprises in 2022, selected and received the highest five-star rating; passed the AA two-tier integrated management system certification; rated by the Jiangsu Pharmaceutical Quality Management Association as an excellent enterprise for the 2023 Jiangsu Pharmaceutical Industry Quality Management (QC) Group Activities; the company is a specialized and innovative small and medium-sized enterprise in Jiangsu Province, a demonstration enterprise for industrial Internet development (benchmark factory category), rated as “AAA” by Oriental Android (Beijing) International Credit Assessment Center “Credit Enterprise”, won the honor of “National Intellectual Property Demonstration Enterprise”, etc.

Company Profile

Short Name-A联环药业
Symbol-A600513
Company NameJIANGSU LIANHUAN PHARMACEUTICAL Co.,Ltd.
Listing DateMar 19, 2003
Issue Price7.88
Shares Offered20.00M share(s)
FoundedFeb 22, 2000
Listed ExchangeSH Stock Exchange
Legal Representativezhenhua qian
General Managerben niu
Secretaryzhenhua qian
Accounting FirmZhonghui Certified Public Accountants (Special General Partnership)
Securities Representativejuan yu
Legal CounselBeijing Jingtian Gongcheng Law Firm Shanghai Branch
Employees877
Phone0514-87813082
Office AddressNo. 9, Health 1st Road, Yangzhou Biohealth Industrial Park, Yangzhou, Jiangsu
Zip Code225127
Registered AddressNo. 9, Health 1st Road, Yangzhou Biohealth Industrial Park, Yangzhou, Jiangsu
Fax0514-87815079
Emaillhgf@lhpharma.com
Business License320000000006964
BusinessPharmaceutical production (produced within the scope specified in the license). It operates and acts as an agent for the import and export business of various types of products and technologies. Authorized use of pharmaceutical-related technology, transfer of results, and service consultation. (For projects requiring approval according to law, business activities can only be carried out after approval by the relevant departments)

Company Executives

  • Name
  • Position
  • Salary
  • zhenhua qian
  • Chairman, Directors, Board Secretary, Strategy Committee Convener, Nomination Committee Members, Member of the Remuneration and Assessment Committee
  • 760.30K
  • bin tu
  • Vice Chairman, Directors
  • 723.10K
  • wendong liu
  • Directors
  • --
  • wenge wu
  • Directors, Audit Committee Member
  • 829.20K
  • chunlai xia
  • Directors, Member of the Strategy Committee
  • --
  • guangji wang
  • Directors, Member of the Strategy Committee
  • --
  • bin zhang
  • Independent Directors, Remuneration and Assessment Committee Convener, Audit Committee Convener
  • 80.00K
  • yiqiao hu
  • Independent Directors, Member of the Remuneration and Assessment Committee, Member of the Strategy Committee, Nomination Committee Convener
  • 80.00K
  • ying chen
  • Independent Directors, Nomination Committee Members, Audit Committee Member
  • 80.00K
  • juan yu
  • Securities Affairs Representative
  • --
  • baochang yu
  • Chairman of the Supervisory Board, Auditors
  • --
  • chunyuan wang
  • Auditors
  • --
  • ben niu
  • General Manager, Chief Engineer
  • 709.80K
  • yi shen
  • Deputy General Manager
  • 674.60K
  • zhangkun hu
  • Deputy General Manager
  • --
  • qingsong chu
  • Deputy General Manager
  • 660.70K
  • hao xue
  • Chief Financial Officer
  • --
  • jing zhang
  • Employee Supervisors
  • 307.50K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
CN
Overall
Symbol
Latest Price
% Chg

No Data